- Cyrus Taraporevala Elected to Pfizer's Board of Directors
- July 01, 2024
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
- June 27, 2024
- Pfizer Declares Third-Quarter 2024 Dividend
- June 26, 2024
- Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
- June 18, 2024
- ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
- June 16, 2024
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- June 14, 2024
- Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- June 01, 2024
- Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
- June 01, 2024
- Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
- May 31, 2024